Rich Small

Richard (Rich) Small is the Chief Executive Officer of Neurotech, a private biotech company focused on developing transformative therapies for chronic eye diseases. He was instrumental in leading Neurotech’s approval of ENCELTO™ (revakinagene taroretcel-lwey) as the first and only FDA approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel) in the United States.

He has led the Neurotech team since 2016 and originally joined as the Company’s Chief Financial Officer in 2007. Rich has more than 30 years of both private and public life sciences experience and greater than 40 years of overall financial and operational management.

Prior to Neurotech, Rich was a founding member of Point Therapeutics, a publicly traded biotechnology company focused on developing treatments for various cancers. He served as Senior Vice President and Chief Financial Officer and contributed to taking the company public and successfully completed an array of private and public equity offerings. Previously, he served as Vice President, Chief Financial Officer at Immulogic Pharmaceutical, Inc., a publicly traded biotechnology company developing treatments for immunological-based disorders where Rich led the completion of multiple licensing deals and several public equity offerings.

Rich started his career in senior management financial and treasury roles with Dennison Manufacturing Company, and the public accounting firm of Coopers and Lybrand, LLC.

He served as a Trustee for the New England College of Optometry from 1995 to 2022, where he was Chair of the Finance and Business Affairs Committee and was a member of the Executive Committee for more than 15 years. Rich holds a BS in Business Administration from Northeastern University in Boston, Massachusetts and is a Certified Public Accountant.